The  8th course is scheduled October 19-27, 2024
John Rex

John H. Rex, MD, FACP

Dr. Rex is a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. He is currently CMO for F2G, Ltd. (an antifungal biotech), is an operating partner with a venture capital group (Advent Life Sciences), and was (2015-2019) a voting member on the US Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB). He also blogs regularly at

His experience includes moving compounds from early preclinical development through all development phases via academic positions (NIH, Bethesda, MD; Univ. of Texas Medical School-Houston) and VP-level roles at a multinational pharmaceutical firm (AstraZeneca). Other past activities include advancing novel regulatory paradigms for antibacterial agents, publications on novel reimbursement models for antibiotics, co-founding of a public-private partnership (CARB-X), co-founding of the New Drugs for Bad Bugs (ND4BB) program of Europe’s Innovative Medicines Initiative (IMI), and a 4-year term as Industry Representative on the FDA Anti-Infective Drugs Advisory Committee (AIDAC, 2007–2011).

Scroll to Top